These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21792901)

  • 41. B cell-Derived IL35 Drives STAT3-Dependent CD8
    Mirlekar B; Michaud D; Lee SJ; Kren NP; Harris C; Greene K; Goldman EC; Gupta GP; Fields RC; Hawkins WG; DeNardo DG; Rashid NU; Yeh JJ; McRee AJ; Vincent BG; Vignali DAA; Pylayeva-Gupta Y
    Cancer Immunol Res; 2020 Mar; 8(3):292-308. PubMed ID: 32024640
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer.
    Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA
    J Immunol; 2006 Dec; 177(11):8191-201. PubMed ID: 17114496
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
    Martínez-Usatorre A; Donda A; Zehn D; Romero P
    J Immunol; 2018 Jul; 201(2):792-803. PubMed ID: 29875150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
    Yin W; Song Y; Liu Q; Wu Y; He R
    Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
    Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
    Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of tumour-infiltrating lymphocytes in a tumour rejection cynomolgus macaque model.
    Satooka H; Ishigaki H; Todo K; Terada K; Agata Y; Itoh Y; Ogasawara K; Hirata T
    Sci Rep; 2020 May; 10(1):8414. PubMed ID: 32439888
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.
    Prinz PU; Mendler AN; Masouris I; Durner L; Oberneder R; Noessner E
    J Immunol; 2012 Jun; 188(12):5990-6000. PubMed ID: 22573804
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
    Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
    Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
    Palmer DC; Balasubramaniam S; Hanada K; Wrzesinski C; Yu Z; Farid S; Theoret MR; Hwang LN; Klebanoff CA; Gattinoni L; Goldstein AL; Yang JC; Restifo NP
    J Immunol; 2004 Dec; 173(12):7209-16. PubMed ID: 15585842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity.
    Yang X; Chu Y; Wang Y; Zhang R; Xiong S
    J Leukoc Biol; 2006 Dec; 80(6):1434-44. PubMed ID: 16980511
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
    Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
    Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
    Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
    Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.
    Jarnicki AG; Lysaght J; Todryk S; Mills KH
    J Immunol; 2006 Jul; 177(2):896-904. PubMed ID: 16818744
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells.
    Rudge G; Barrett SP; Scott B; van Driel IR
    J Immunol; 2007 Apr; 178(7):4089-96. PubMed ID: 17371963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune-mediated antitumor effect by type 2 diabetes drug, metformin.
    Eikawa S; Nishida M; Mizukami S; Yamazaki C; Nakayama E; Udono H
    Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1809-14. PubMed ID: 25624476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
    Hensbergen PJ; Wijnands PG; Schreurs MW; Scheper RJ; Willemze R; Tensen CP
    J Immunother; 2005; 28(4):343-51. PubMed ID: 16000952
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors.
    Chheda ZS; Sharma RK; Jala VR; Luster AD; Haribabu B
    J Immunol; 2016 Sep; 197(5):2016-26. PubMed ID: 27465528
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells.
    González-Martín A; Gómez L; Lustgarten J; Mira E; Mañes S
    Cancer Res; 2011 Aug; 71(16):5455-66. PubMed ID: 21715565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.